Intranasal Immunization with DOTAP Cationic Liposomes Combined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and Systemic Immune Responses in Mice. 2015

Rui Tada, and Akira Hidaka, and Naoko Iwase, and Saeko Takahashi, and Yuki Yamakita, and Tomoko Iwata, and Shoko Muto, and Emi Sato, and Noriko Takayama, and Emi Honjo, and Hiroshi Kiyono, and Jun Kunisawa, and Yukihiko Aramaki
Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.

Despite the progress made by modern medicine, infectious diseases remain one of the most important threats to human health. Vaccination against pathogens is one of the primary methods used to prevent and treat infectious diseases that cause illness and death. Vaccines administered by the mucosal route are potentially a promising strategy to combat infectious diseases since mucosal surfaces are a major route of entry for most pathogens. However, this route of vaccination is not widely used in the clinic due to the lack of a safe and effective mucosal adjuvant. Therefore, the development of safe and effective mucosal adjuvants is key to preventing infectious diseases by enabling the use of mucosal vaccines in the clinic. In this study, we show that intranasal administration of a cationic liposome composed of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl] (DC-chol) (DOTAP/DC-chol liposome) has a potent mucosal adjuvant effect in mice. Intranasal vaccination with ovalbumin (OVA) in combination with DOTAP/DC-chol liposomes induced the production of OVA-specific IgA in nasal tissues and increased serum IgG1 levels, suggesting that the cationic DOTAP/DC-chol liposome leads to the induction of a Th2 immune response. Additionally, nasal-associated lymphoid tissue and splenocytes from mice treated with OVA plus DOTAP/DC-chol liposome showed high levels of IL-4 expression. DOTAP/DC-chol liposomes also enhanced OVA uptake by CD11c+ dendritic cells in nasal-associated lymphoid tissue. These data demonstrate that DOTAP/DC-chol liposomes elicit immune responses via an antigen-specific Th2 reaction. These results suggest that cationic liposomes merit further development as a mucosal adjuvant for vaccination against infectious diseases.

UI MeSH Term Description Entries
D007110 Immunity, Active Resistance to a disease agent resulting from the production of specific antibodies by the host, either after exposure to the disease or after vaccination. Active Immune Response,Active Immune Responses,Active Immunities,Active Immunity,Immune Response, Active,Immune Responses, Active,Immunities, Active,Response, Active Immune,Responses, Active Immune
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D010047 Ovalbumin An albumin obtained from the white of eggs. It is a member of the serpin superfamily. Serpin B14
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D005229 Fatty Acids, Monounsaturated Fatty acids which are unsaturated in only one position. Monounsaturated Fatty Acid,Acid, Monounsaturated Fatty,Acids, Monounsaturated Fatty,Fatty Acid, Monounsaturated,Monounsaturated Fatty Acids
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000281 Administration, Intranasal Delivery of medications through the nasal mucosa. Drug Administration, Intranasal,Administration, Intranasal Drug,Administration, Nasal,Intranasal Administration,Intranasal Drug Administration,Administrations, Intranasal,Administrations, Intranasal Drug,Administrations, Nasal,Drug Administrations, Intranasal,Intranasal Administrations,Intranasal Drug Administrations,Nasal Administration,Nasal Administrations
D000644 Quaternary Ammonium Compounds Derivatives of ammonium compounds, NH4+ Y-, in which all four of the hydrogens bonded to nitrogen have been replaced with hydrocarbyl groups. These are distinguished from IMINES which are RN Quaternary Ammonium Compound,Ammonium Compound, Quaternary,Ammonium Compounds, Quaternary,Compound, Quaternary Ammonium
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations

Related Publications

Rui Tada, and Akira Hidaka, and Naoko Iwase, and Saeko Takahashi, and Yuki Yamakita, and Tomoko Iwata, and Shoko Muto, and Emi Sato, and Noriko Takayama, and Emi Honjo, and Hiroshi Kiyono, and Jun Kunisawa, and Yukihiko Aramaki
March 2007, Vaccine,
Rui Tada, and Akira Hidaka, and Naoko Iwase, and Saeko Takahashi, and Yuki Yamakita, and Tomoko Iwata, and Shoko Muto, and Emi Sato, and Noriko Takayama, and Emi Honjo, and Hiroshi Kiyono, and Jun Kunisawa, and Yukihiko Aramaki
April 1995, European journal of immunology,
Rui Tada, and Akira Hidaka, and Naoko Iwase, and Saeko Takahashi, and Yuki Yamakita, and Tomoko Iwata, and Shoko Muto, and Emi Sato, and Noriko Takayama, and Emi Honjo, and Hiroshi Kiyono, and Jun Kunisawa, and Yukihiko Aramaki
December 2015, Auris, nasus, larynx,
Rui Tada, and Akira Hidaka, and Naoko Iwase, and Saeko Takahashi, and Yuki Yamakita, and Tomoko Iwata, and Shoko Muto, and Emi Sato, and Noriko Takayama, and Emi Honjo, and Hiroshi Kiyono, and Jun Kunisawa, and Yukihiko Aramaki
March 2010, FEMS immunology and medical microbiology,
Rui Tada, and Akira Hidaka, and Naoko Iwase, and Saeko Takahashi, and Yuki Yamakita, and Tomoko Iwata, and Shoko Muto, and Emi Sato, and Noriko Takayama, and Emi Honjo, and Hiroshi Kiyono, and Jun Kunisawa, and Yukihiko Aramaki
August 2017, Auris, nasus, larynx,
Rui Tada, and Akira Hidaka, and Naoko Iwase, and Saeko Takahashi, and Yuki Yamakita, and Tomoko Iwata, and Shoko Muto, and Emi Sato, and Noriko Takayama, and Emi Honjo, and Hiroshi Kiyono, and Jun Kunisawa, and Yukihiko Aramaki
December 2007, Vaccine,
Rui Tada, and Akira Hidaka, and Naoko Iwase, and Saeko Takahashi, and Yuki Yamakita, and Tomoko Iwata, and Shoko Muto, and Emi Sato, and Noriko Takayama, and Emi Honjo, and Hiroshi Kiyono, and Jun Kunisawa, and Yukihiko Aramaki
July 2016, Microbiology and immunology,
Rui Tada, and Akira Hidaka, and Naoko Iwase, and Saeko Takahashi, and Yuki Yamakita, and Tomoko Iwata, and Shoko Muto, and Emi Sato, and Noriko Takayama, and Emi Honjo, and Hiroshi Kiyono, and Jun Kunisawa, and Yukihiko Aramaki
October 2000, Molecular medicine (Cambridge, Mass.),
Rui Tada, and Akira Hidaka, and Naoko Iwase, and Saeko Takahashi, and Yuki Yamakita, and Tomoko Iwata, and Shoko Muto, and Emi Sato, and Noriko Takayama, and Emi Honjo, and Hiroshi Kiyono, and Jun Kunisawa, and Yukihiko Aramaki
September 2004, Vaccine,
Rui Tada, and Akira Hidaka, and Naoko Iwase, and Saeko Takahashi, and Yuki Yamakita, and Tomoko Iwata, and Shoko Muto, and Emi Sato, and Noriko Takayama, and Emi Honjo, and Hiroshi Kiyono, and Jun Kunisawa, and Yukihiko Aramaki
September 2008, Vaccine,
Copied contents to your clipboard!